States Lag in Committing Tobacco Funds to Antismoking Efforts

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 10
Volume 8
Issue 10

WASHINGTON-Only six of the states that settled their lawsuit with the tobacco industry last year have so far “provided enough new funding for truly comprehensive tobacco prevention and cessation programs,” according to a new report by the Campaign for Tobacco-Free Kids and the American Heart Association. The six states are Hawaii, Maryland, Minnesota, Vermont, New Jersey, and Washington.

WASHINGTON—Only six of the states that settled their lawsuit with the tobacco industry last year have so far “provided enough new funding for truly comprehensive tobacco prevention and cessation programs,” according to a new report by the Campaign for Tobacco-Free Kids and the American Heart Association. The six states are Hawaii, Maryland, Minnesota, Vermont, New Jersey, and Washington.

Ten other states will dedicate less of their funds to prevention than the Center for Disease Control and Prevention recommends for an effective program. Other states have refused to specifically provide prevention funds or have yet to make a decision about antismoking programs.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
2 experts are featured in this series.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Related Content